TED · Award
Oncology Generics Medicines
A public procurement published by The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority") via TED.
TEDAward
- —
- Award value
- £51.8m
- Tender value
- 0
- Suppliers
- 0
- Awards
- 1
- Notices
- Award
- Stage
Key details
- Buyer
- The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")
- Source
- TED
- Lifecycle stage
- Award
- Status
- —
- CPV classification
- 33600000
- Currency
- GBP
- Total award value
- —
- Tender value
- £51,839,881
- First published
- 12 Aug 2020
- Last updated
- 12 Aug 2020
Notice timeline
Every published notice in this procurement's lifecycle.
Frameworks & programmes
More from The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")
Cardiovascular and Respiratory Medicines
Award · TEDENT, Ophthalmology and Skin Medicines/Medical Devices
Tender · TEDAntibiotic and Genito Urinary Branded and Generic Medicines
Tender · TEDENT, Ophthalmology and Skin Medicines/Medical Devices
Award · TEDRadiotherapy, Linear Accelerator, for Highland Health Board and Tayside Health Board
Tender · TEDAnalgesics and Anaesthetics, Musculoskeletal and Joint Disease Generic Medicine
Tender · TEDFAQs about this procurement
Who is the buyer for "Oncology Generics Medicines"?
Oncology Generics Medicines is a UK public-sector procurement published by The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority") via TED.
Has "Oncology Generics Medicines" been awarded?
No award has been recorded yet. The current lifecycle stage is "Award".
What is "Oncology Generics Medicines" worth?
The reported tender value is £51,839,881.
When was "Oncology Generics Medicines" published?
It was first published on 12 Aug 2020 and last updated on 12 Aug 2020, across 1 notice.
Track procurements like this one
Enable monitors the entire UK public-contract pipeline — get alerts on buyers, suppliers and frameworks that matter to you.
Get in touch with Enable